Iktos and Nerviano Medical Sciences S.r.l (NMS), a leading Italian clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, announced a collaboration agreement in AI for unprecedented kinase project. As per the agreement, NMS will leverage Iktos’s expertise in drug design services, with the ultimate goal of identifying at least one promising candidate molecule. Follow the link for the full press release.
